Zealand Pharma A/s Stock
Zealand Pharma A/s Stock
A very strong showing by Zealand Pharma A/s today, with an increase of €1.74 (3.970%) compared to yesterday's price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Zealand Pharma A/s stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Zealand Pharma A/s in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Zealand Pharma A/s vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zealand Pharma A/s | 3.970% | 4.316% | 22.829% | -1.254% | -28.603% | 42.217% | 99.650% |
| Saniona AB | -1.160% | -1.080% | 3.927% | 60.081% | -37.904% | 54.876% | -31.156% |
| NanoViricides Inc. | 1.740% | -6.400% | -17.606% | -9.302% | 25.806% | 0.000% | -64.631% |
| Ocuphire Pharma Inc. | 2.520% | 4.348% | -2.890% | 251.464% | 99.762% | -13.625% | -17.647% |
News
Entain H1 Earnings Call Highlights
Key Points
- Interested in Entain Plc? Here are five stocks we like better.
- Entain reported strong first-half growth: Online net gaming revenue increased 7% in constant currency, group EBITDA
LENZ Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in LENZ Therapeutics, Inc.? Here are five stocks we like better.
- Q2 revenue reached $5.5 million, including more than $1.7 million in VIZZ product revenue and $3.8
JBS Q2 Earnings Call Highlights
Key Points
- Interested in Jbs N.V.? Here are five stocks we like better.
- JBS reported record second-quarter sales of $24 billion, with adjusted EBITDA of $1.43 billion under IFRS and adjusted net